Artificial intelligence is a powerful tool used for predicting the disease’s future trend and to explore the possible treatments ,based on the quality data. The biotechnology company AbCellera is leveraging machine learning techniques and models to develop the therapies based on antibodies from those patients who have been able to recover successfully from this disease.
Using this artificial intelligence almost 500 antibodies have been identified as the possible ones to be used use in future for the Coronavirus treatment.
“AbCellera’s platform has delivered, with unprecedented speed, by far the world’s largest panel of anti-SAR-CoV-2 antibodies. In 11 days, we’ve discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak, moved into functional testing with global experts in virology, and signed a co-development agreement with one of the world’s leading biopharmaceutical companies.” said the CEO Carl Hanse, AbCellera Biologics.